Switch from Immediate-release Pramipexole to Extended-release Pramipexole: The Safety and Efficacy Characteristics of Sixty-eight Patients
| Autor: | Oğuzhan Herdi, Müge Kuzu, Muhittin Cenk Akbostanci, İnci Şule Özer, Sabiha Tezcan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Levodopa Nausea dopamine agonist 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Entacapone RC346-429 Adverse effect extended-release pramipexole Rasagiline Pramipexole business.industry Amantadine Parkinson disease 030104 developmental biology chemistry Dyskinesia Anesthesia Medicine Neurology. Diseases of the nervous system Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Türk Nöroloji Dergisi, Vol 22, Iss 3, Pp 114-116 (2016) |
| ISSN: | 1301-062X |
| Popis: | Objective: To evaluate the safety and efficacy of switching from immediate-release pramipexole (pex) to extended-release pramipexole (pex-ER). Materials and Methods: Pex-ER became available in Turkey about a year ago, since then we documented satisfactory information on patients (26 women; 38%) who were switched from pex to pex-ER. We recorded pre- and post-switch pex and levodopa, equivalent doses of other anti-parkinsonian medication, and analyzed the frequency and nature of reported adverse effects. Results: The mean age of the patients was 63.3 years (range, 44-88 years), and the mean disease duration was 7.1 years (range, 1-27 years). The other drugs were levodopa (57 patients, 82.6%), entacapone (24 patients, 34.58%), rasagiline (20 patients, 29%), amantadine (18 patients, 26.1%), and apomorphine (six patients, 8.7%). Switch from pex to pex-ER was uneventful in 62 (91.2%) patients. Adverse events were reported in six (8.8%) patients: ankle swelling (two patients), nausea (one patient), dyskinesia (one patient), hypersexuality (one patient), and psychosis (one patient). Problems resolved with further medication change in two patients. Four patients preferred to return to pex. Conclusion: The great majority of patients (91.2%) switched from three times daily pex to once daily pex-ER uneventfully. A slight increase in pex daily dose, which was tailored according to patients’ symptomatic needs, resulted in an increase in post-switch levodopa equivalent doses. Our experience is compatible with previously reported studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|